Cheng Y, et al. - In this prospective case series, authors quantified 13 eyes of 12 subjects to study the therapeutic outcome of the intravitreal anti-vascular endothelial growth factor on myopic choroidal neovascularization (CNV). They noticed a significant improvement in best-corrected visual acuity with decreased central macular thickness, greatest linear dimension, intraretinal fluid, or subretinal fluid 7 days or 30 days after treatment. They presented myopic CNV as irregular or nearly round closed mass at the level of the outer retinal layer in all eyes at the primary visit. The size of the selected CNV area and flow area were further decreased 30 days after treatment.